Articles from Imricor Medical Systems, Inc.

Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the launch of Imricor Cardiovascular, a new vertical that expands the interventional MR (iMR) market for Imricor alongside its electrophysiology and ablation business. Following recent FDA clearances for NorthStar® and the Vision-MR® Diagnostic Catheter, Imricor Cardiovascular gives U.S. hospitals an opportunity to establish early leadership in radiation-free cardiac catheterization by performing these procedures in an iMR lab utilizing the superior imaging power of magnetic resonance (MR).

Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR) is pleased to announce the U.S. commercial launch of its NorthStar® Mapping System.

Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first Ischemic Ventricular Tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab.

Imricor Medical Systems, Inc. (Company or Imricor) (ASX:IMR) the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Vision-MR Ablation Catheter 2.0 for Treatment of Type I Atrial Flutter (VISABL-AFL) IDE clinical trial, commenced with two procedures performed at the Cardiovascular Institute of South Paris (ICPS) (https://icps.fr).

Imricor Medical Systems, Inc. (ASX:IMR) Imricor, the global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation products, is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with GE HealthCare.